Travere Therapeutics, Inc. (TVTX) Cash Flow Statement

The wide variance between net income and operating cash flow suggests that accounting accruals and non-cash items, such as stock-based compensation and amortization, are heavily distorting the underlying cash generation profile. Investors should monitor whether the company can achieve a more stable conversion ratio as the sparsentan launch matures and revenue recognition becomes more predictable.

The erratic FCF margins, ranging from -168.7% to 47.1%, underscore the company's reliance on external capital to fund its ongoing operations. This trajectory implies that the firm has not yet reached the inflection point where incremental revenue from sparsentan sufficiently covers the heavy R&D and SG&A requirements.

These sharp swings in working capital suggest that the company's cash position is highly sensitive to the timing of collections and inventory stocking patterns. Analysts should investigate whether these fluctuations represent genuine operational efficiency gains or merely temporary timing differences that could reverse in subsequent quarters.

The persistent level of capital intensity suggests that the company is still in a heavy investment phase, likely prioritizing infrastructure to support long-term market penetration. This level of spending warrants further investigation to determine if these costs are primarily maintenance-related or if they represent continued growth-oriented capacity expansion.